Design of therapeutic antibody formulations for subcutaneous delivery

Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody approved for the treatment of head & neck cancer and colorectal cancer. The current administration of cetuximab is via intravenous infusion. Subcutaneous injections which does not require hospital stays is a preferred route by both patients and health care professionals. In a current study a stable high concentration formulation for cetuximab was developed, which has potential to be administered as subcutaneous injections for the cancer patients in future.